Clinical Trial

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-01-30; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Status change: Not Yet Recruiting → Recruiting 2024-03-01
Trial Details
NCT Number NCT06246110
Lead Sponsor Eikon Therapeutics
Conditions NSCLC
Enrollment 70 participants
Start Date 2024-02-06
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-28